INTANGIBLE ASSETS AND GOODWILL (Details) (USD $)				12 Months Ended	3 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2012 Acquired IPR&D	Sep. 30, 2012 Acquired IPR&D U.S. Dermatology	Jun. 30, 2012 Acquired IPR&D U.S. Dermatology	Dec. 31, 2012 Acquired IPR&D U.S. Dermatology and U.S. Neurology and Other	Dec. 31, 2011 Acquired IPR&D U.S. Dermatology and U.S. Neurology and Other	Dec. 31, 2012 Product brands	Dec. 31, 2011 Product brands	Dec. 31, 2012 Corporate brands	Dec. 31, 2011 Corporate brands	Dec. 31, 2012 Product rights	Dec. 31, 2011 Product rights	Dec. 31, 2012 Partner relationships	Dec. 31, 2011 Partner relationships	Dec. 31, 2012 Out-licensed technology and other	Dec. 31, 2011 Out-licensed technology and other
Finite-lived intangible assets:
Gross Carrying Amount	$ 10,759,419,000		$ 8,220,164,000						$ 7,968,318,000	$ 6,428,304,000	$ 284,287,000	$ 179,752,000	$ 2,110,350,000	$ 1,302,140,000	$ 187,012,000	$ 135,095,000	$ 209,452,000	$ 174,873,000
Accumulated Amortization	(1,997,626,000)		(1,109,990,000)						(1,345,367,000)	(737,876,000)	(25,336,000)	(10,630,000)	(525,186,000)	(306,936,000)	(44,230,000)	(15,633,000)	(57,507,000)	(38,915,000)
Net Carrying Amount	8,761,793,000		7,110,174,000						6,622,951,000	5,690,428,000	258,951,000	169,122,000	1,585,164,000	995,204,000	142,782,000	119,462,000	151,945,000	135,958,000
Indefinite-lived intangible assets:
Acquired IPR&D	546,876,000		531,304,000
Total intangible assets
Gross carrying amount	11,306,295,000		8,751,468,000
Net Carrying Amount	9,308,669,000		7,641,478,000
Payment made for termination of research and development commitment		12,000,000
Impairment charges				24,700,000	133,400,000	4,300,000	24,700,000	105,200,000
Accumulated Amortization	$ (1,997,626,000)		$ (1,109,990,000)						$ (1,345,367,000)	$ (737,876,000)	$ (25,336,000)	$ (10,630,000)	$ (525,186,000)	$ (306,936,000)	$ (44,230,000)	$ (15,633,000)	$ (57,507,000)	$ (38,915,000)